Newomics Announces a Co-Marketing Agreement to Improve Performance of High-throughput Workflows

BERKELEY, Calif.–(BUSINESS WIRE)–Newomics Inc., a commercial-stage biotechnology company that sells and develops mass spectrometry products, services and diagnostics, today announced a co-marketing agreement with Thermo Fisher Scientific, the world leader in serving science. The companies will engage in joint marketing of multinozzle emitters from Newomics and liquid chromatography (LC) and mass spectrometry (MS) systems from Thermo Fisher.

The Newomics award-winning silicon multinozzle emitters (M3 emitters) enable optimization of sensitivity, throughput and robustness for LC-MS by splitting the LC eluent evenly into multiple flows at the emitter, thereby dramatically enhancing the ionization efficiency. The first commercially-available M3 emitter has been optimized for microflow LC – nanospray MS and can easily be configured for the Thermo Scientific microflow LC-MS systems and the Thermo Scientific Nanospray Flex ion source.

“We are excited about the Co-Marketing agreement with Thermo Fisher Scientific, a global leader in liquid chromatography and mass spectrometry. This was built upon our close collaborations over the last 5 years with multiple Thermo teams including those in R&D and Omics Marketing,” said Daojing Wang, Founder and CEO, Newomics. “Going forward, we will work closely with Thermo to further optimize our joint platform for high-throughput workflows to meet the diverse needs from our customers.”

“The M3 emitter has the potential to be a transformative technology,” said Ken Miller, vice president, life sciences mass spectrometry, Thermo Fisher Scientific. “The ability to combine the robustness of microflow LC with the sensitivity of nanospray MS should allow for the expanded use of LC-MS in translational proteomics applications. We look forward to expanding our collaborations with Newomics to deliver novel LC-MS solutions to serve the high-throughput needs of our clinical research customers.”

About Newomics

Newomics Inc. is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The company’s first product, the M3 multinozzle emitter for MS, enables the robustness of microflow LC and the sensitivity of nanospray ionization MS. The plug-and-play M3 emitters are currently interfaced to diverse MS instruments and can be ordered at www.newomics.com.

Contacts

Steven Bodovitz
Newomics Inc.
(510) 833-2811
sbodovitz@newomics.com